![Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis - European Urology Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/870b8bc0-fc65-4a64-9840-e4f0f949bbab/gr1_lrg.jpg)
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis - European Urology
![Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection | Business Wire Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection | Business Wire](https://mms.businesswire.com/media/20200316005177/en/739014/23/teva_RGB_JPEG.jpg)
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection | Business Wire
![Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial - European Journal of Cancer Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7fff8e5c-d3f7-4e1d-8b6e-03c83ea1513e/ga1_lrg.jpg)
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial - European Journal of Cancer
![Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial - The Lancet Oncology Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2064157560/2065867280/gr1.gif)
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial - The Lancet Oncology
![Physical and chemical stability of docetaxel infusions in polyolef in bags containing 0.9% sodium chloride or 5% glucose at 5°C and 25°C | Semantic Scholar Physical and chemical stability of docetaxel infusions in polyolef in bags containing 0.9% sodium chloride or 5% glucose at 5°C and 25°C | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/499ab0948641583735b2a498c52b231f4f9dec55/3-Table2-1.png)